CATX — Perspective Therapeutics, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 728387 ·
Last close
$0.86
Market Cap
$103.84M
52W High
$6.16
52W Low
$0.78
ADV30
3,499,672
Next earnings
2026-11-09
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -34,322,000 -32,442,000 365,682,000 41,042,000 71,002,000
Jun 2026 0 — -29,258,000 -26,786,000 392,025,000 48,488,000 68,162,000
Mar 2026 0 — -28,281,000 -26,189,000 410,769,000 53,972,000 63,331,000
Dec 2025 0 — -39,832,000 -37,490,000 266,972,000 30,629,000 59,941,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-108,127,000
Investing CF
$-42,266,000
Financing CF
$164,673,000
CapEx
$-30,663,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.09
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-387,815,000
Inventory
—
Receivables
$269,000
ST Investments
$188,388,000
EBIT TTM
$-117,119,000
Pretax Income TTM
$-117,424,000
Interest Exp TTM
$305,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$220,000
EBITDA
$-127,229,000
Free Cash Flow
$-78,374,248
Enterprise Value
$-84,127,360
Total Cash
$201,695,008
Total Debt
$3,680,000
Shares Out
120,758,815
Trailing EPS
$-1.25
Book Value
$2.58
ROE
-45.9%
ROA
-24.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -113,564,000 -103,121,000 266,972,000 59,941,000 207,031,000 -82,484,000
Dec 2024 0 -66,797,000 -79,279,000 341,101,000 50,433,000 290,668,000 -18,294,000
Dec 2023 0 -40,941,000 -46,508,000 97,891,000 22,712,000 75,179,000 -36,913,000
Jun 2022 10,795,000 -7,391,000 -7,272,000 64,439,000 3,162,000 61,277,000 -7,710,000

TTM Snapshot

Revenues TTM
$8,115,000
NetIncome TTM
$-116,434,000
OpCashFlow TTM
—
Assets (Latest)
$392,025,000
Forward EPS
$-1.03

Peers — same industry

TickerNameMarket CapLastDaily %
OKUR OnKure Therapeutics, Inc. $104.50M $2.58 —
NERV Minerva Neurosciences, Inc. $103.13M $2.16 —
ORGO Organogenesis Holdings Inc. $105.35M $0.81 —
OGI ORGANIGRAM GLOBAL INC. $101.90M $0.71 —
NRXP NRX Pharmaceuticals, Inc. $106.07M $2.45 —

News headlines (Yahoo Finance, 1h cache)

Perspective Therapeutics: Q3 Earnings Snapshot
2026-11-09 21:56 · Yahoo
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
2026-11-09 21:30 · Yahoo
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
2026-11-06 01:10 · Yahoo
Perspective Therapeutics (CATX) Stock Sees Fair Value Moves Lower As Analysts Weigh Lead 212 Risks
2026-11-01 02:12 · Yahoo
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
2026-10-23 21:02 · Yahoo
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced
2026-10-23 14:49 · Yahoo
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
2026-10-08 10:16 · Yahoo
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
2026-10-02 15:46 · Yahoo
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
2026-09-14 10:16 · Yahoo
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
2026-09-11 10:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.